Technical Data
C0075-29
CA19-9 Cancer Antigen (Pancreatic, GI or Ovarian Tumor Antigen, Sialyl Lewis a)
Description:
CA19–9, a carbohydrate antigenic determinant identified as a sialylated lacto-N-fucopentose II, is an oligosaccharide which is biochemically related to the sialyl Lewis a (sialyl Lea) blood group substance. CA19–9 is detected is most adenocarcinomas of the pancreas and stomach, and many colon and gall bladder cancers. The antigen is also expressed in approximately half of primary and metastatic ovarian tumors. The immunostaining pattern of CA19–9 antigen may be of value in predicting the prognosis of patients with colorectal carcinoma. In normal tissues, positive staining is observed in columnar epithelium of the pancreas, stomach, liver, gall bladder and in bronchial glands of the lung.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Immunohistochemistry: Frozen and formalin-fixed, paraffin embedded tissue sections. Epitope retrieval and enzyme digestion are not required.
Optimal dilutions to be determined by the researcher.

Positive Control:
Human colorectal adenocarcinoma tissue

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG13G37Purified
SizeStorageShippingSourceHost
500ul-20°CBlue IceHumanMouse
Concentration:
Not Determined
Immunogen:
Puri ed human CA19–9 protein. Expected Staining Pattern: Membrane
Purity:
Purified
Form
Supplied as a liquid in PBS, pH 7.2, 1% BSA, 0.1% sodium azide.
Specificity:
Recognizes human CA19-9 Cancer Antigen.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Koprowski, H., et al., Somatic Cell Mol. Genet. 5: 957-972 (1979). 2. Magnani, J.L., et al., J. Biol. Chem. 257: 14,365-14,369 (1982). 3. Shimono, R., et al., Am. J. Gastroenterol. 89(1): 101-105 (1994). 4. Elias, J.M., et al., Am. J. Clin. Pathol. 92: 62-67 (1989). 5. Shi, Z.R., et al., J. Histochemistry and Cytochemistry 36(3): 317-322 (1988). 6. Kiernan, J.A., Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press (1981). 7. Sheehan, D.C. and Hrapchak, B.B., Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co. (1980). 8. Taylor and Cote. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist. 2nd Ed. W.B. Saunders Co. Philadelphia, (1994). 9. Elias, J.M., et al., Am. J. Clin. Path. 92: 836 (1989). 10. O’Leary, T.J., et al., Quality assurance for immunocytochemistry; Proposed guideline. MM4-P. National Committee for Clinical Laboratory Standards (NCCLS). Wayne, PA., 1-46. (1997). 11. College of American Pathologists (CAP) Certi cation Program for Immunohistochemistry. North eld, IL. Http://www.cap.org (800) 323–4040. 12. Koretzik, K., et al., Histochemistry. 86: 471-478 (1987).